If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase. 22%, Tetraphase Pharmaceuticals Inc&39;s debt growth rate surpasses merely 1. Find the latest Tetraphase Pharmaceuticals, Inc (TTPH) stock quote, history, news and other vital information to help you with tetraphase pharmaceuticals stock your stock trading and investing. What is Tetraphase pharmaceutical?
Per the agreement, AcelRx agreed to acquire Tetraphase in an all-stock transaction valued at approximately . Tetraphase Pharmaceuticals Inc stock rating and analysis - : a summary of key financial strength and profitability metrics. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. · View %COMPANY_NAME% TTPH investment & stock information. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. TTPH stock quote, chart and news. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Get Tetraphase Pharmaceuticals, Inc.
· Press Releases J. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click TetraPhase Pharmaceuticals (TTPH). 81% of about US stocks. --(BUSINESS tetraphase pharmaceuticals stock WIRE)--Sep. 200 USD at, but your current investment may be devalued in the future. · Tetraphase equityholders would also be entitled to receive, for each share of Tetraphase common stock, one non-tradeable CVR, the holders of which will be entitled to receive payments of up to an. 26, -- Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals (NASDAQ:TTPH) Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months.
The following presents a detailed Tetraphase Pharmaceuticals stock price history for your review. Tel| Fax| CONTACT AND MEDICAL INFORMATION. Here&39;s Why Tetraphase Pharmaceuticals Rose as Much as 26.
6303 shares of AcelRx common stock, subject to adjustment in certain. 8 analysts have issued 1 year pharmaceuticals target prices for Tetraphase Pharmaceuticals&39; shares. NYSEMkt Updated 8:00 PM. 00 per share of Tetraphase common stock (including common stock. · Under the terms of the merger agreement, each share of Tetraphase common stock will be converted into the right to receive 0.
("AcelRx") and Consolidation Merger Sub, Inc. Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “TTPH“, or clicking on a stock ticker in the tag cloud at the foot of this article. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc.
The Tetraphase Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Tetraphase shareholders to receive 14. 76 million during the quarter, compared to analysts&39; expectations of . engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. · Investors in Tetraphase Pharmaceuticals, Inc. TTPH Stock Summary. The company announced a stock offering that will bolster its balance sheet but also dilute current investors.
0M in cash plus an additional . 480 Arsenal Way, Suite 100, Watertown, MA 02472. is a clinical-stage biopharmaceutical company.
is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including. On average, they anticipate Tetraphase Pharmaceuticals&39; stock price to reach . Explore commentary on Tetraphase Pharmaceuticals, Inc. &39;s stock price today. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for. 03%, a number that bests only 2. With a year-over-year growth in debt of -92.
If you are looking for stocks with good return, Tetraphase Pharmaceuticals, Inc. 31) EPS for the quarter, beating the consensus estimate of (. Stock analysis for Tetraphase Pharmaceuticals Inc (TTPH) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 6303 share of AcelRx stock for each share they hold in Tetraphase, and a CVR, which will give the holders the right to receive. It also engages in the development of tetraphase pharmaceuticals stock product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections.
· Tetraphase Pharmaceuticals (NASDAQ: TTPH) discloses that it received an unsolicited bid yesterday from Melinta Therapeutics (NASDAQ: MLNT) for . The biopharmaceutical company earned . 8% Today Maxx Chatsko | Jul. Investing in stocks, such as Tetraphase Pharmaceuticals, is an excellent way to grow wealth. 00 in the next twelve months. Tetraphase Pharmaceuticals, Inc.
(Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, announced today that it will effect a 1-for-20 reverse stock split of its. Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th. , a wholly owned subsidiary of La Jolla Pharmaceutical Company. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. Get the latest %COMPANY_NAME% TTPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. A high-level overview of Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) issued its earnings results on Thursday, May, 7th. How much is Tetraphase stock?
To help provide a sense of the short to tetraphase pharmaceuticals stock long-term trend, included is an interactive Tetraphase Pharmaceuticals stock chart which you can easily adjust to the time frame of your choosing (e. 5M payable under. · Under the terms of the definitive merger agreement, the upfront cash consideration in the transaction will be as follows: (i) . In March, the Company announced the execution of a definitive merger agreement pursuant to which AcelRx Pharmaceuticals, Inc. · Tetraphase Pharmaceuticals, Inc. · Tetraphase Pharmaceuticals, Inc.
using the scroll bar or pinch and zoom on a touch screen). real time quote is equal to 2. with respect to the acquisition tetraphase of Tetraphase by AcelRx, pursuant to which each outstanding share of Tetraphase common stock. · AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals AcelRx to acquire Tetraphase in a stock for stock transaction. When does Tetraphase release earnings? 6% of AcelRx fully diluted shares.
Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. · Get detailed information on Tetraphase Pharmaceuticals stock (NASDAQ: TTPH), including today’s stock quote, real-time price, financial history, charts, and more. AcelRx shareholders will own 85. Their forecasts range from . Revenue growth over the past 12 months for Tetraphase Pharmaceuticals Inc comes tetraphase pharmaceuticals stock in at -57.
View detailed financial information, real-time news, videos, quotes and analysis on Tetraphase Pharmaceuticals, Inc. 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. The agreement provided for Tetraphase shareholders receiving 0.
stock can be a bad, high-risk 1-year investment option. Tetraphase also previously announced that it had entered into a merger agreement, dated as of Ma (the "AcelRx Merger Agreement"), with AcelRx Pharmaceuticals, Inc. What are the ratings for Tetraphase?
TTPH Quick Quote TTPH Positive Net Change. · Stocks such as Tetraphase Pharmaceuticals and Chimerix should act as a reminder to all small-cap biopharmaceutical investors they are taking huge risks when they put money to work in these names,. The biopharmaceutical company reported (. 4% of the combined entity while Tetraphase. Tetraphase Pharmaceuticals. La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. (Nasdaq: ACRX) would acquire Tetraphase in a stock for stock.
View Earnings Estimates for Tetraphase Pharmaceuticals. tetraphase pharmaceuticals stock " View analyst ratings for Tetraphase Pharmaceuticals. 98% of the US stocks we&39;re tracking. TETRAPHASE INVESTOR ALERT By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy Of Price And Process In Proposed Sale Of Tetraphase Pharmaceuticals, Inc. (TTPH) need to pay close attention to the stock based on moves in the options market lately. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold.
-> Stocks to hold for 30 years
-> Name of american stock exchange